Jianglong Shipbuilding (300589.SZ) signs a shipbuilding contract worth USD 39.98 million.
Jianglong Shipbuilding (300589.SZ) announced that on September 29, 2026, the company signed two "78-meter Multi-Purpose Offshore Supply Vessel Construction Contracts" with Customer 1, with a total contract value of USD 39.98 million (equivalent to approximately RMB 270 million). Delivery schedule: the first vessel to be delivered on or before June 19, 2028; the second vessel to be delivered on or before August 18, 2028.
Jianglong Shipbuilding (300589.SZ) announced that on September 29, 2026, the company signed two "78-meter Multi-Purpose Offshore Supply Vessel Construction Contracts" with Customer 1, with a total contract value of USD 39.98 million (equivalent to approximately RMB 270 million). Delivery schedule: the first vessel to be delivered on or before June 19, 2028; the second vessel to be delivered on or before August 18, 2028.
The total contract value of USD 39.98 million accounts for 38.35% of the company's audited operating revenue for 2025. The signing of the contract marks that the company's offshore engineering vessel R&D and construction capabilities have once again gained recognition in the international market, effectively expanding its offshore equipment business footprint, continuously consolidating its core competitive advantages in the offshore equipment sector, and representing an important breakthrough in the company's internationalization strategy. It is of positive significance for the company to further explore the international high-end market. If the contract is successfully performed, it will have a positive impact on the company's operating performance in future years.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

HARBIN BANK (06138) Enhances and Expands Agricultural Services to Support High-Quality Development of Agriculture in Heilongjiang

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.
Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

HARBIN BANK (06138) Enhances and Expands Agricultural Services to Support High-Quality Development of Agriculture in Heilongjiang

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.






